Increasing Survival of Patients with Severe SARS-CoV-2 Infection and/or Multi Organ Failure by up to 30% with ADVOS - ADVanced Organ Support

Informazioni relative al progetto

ADVOS-COVID-19

ID dell’accordo di sovvenzione: 961745

DOI

10.3030/961745

Progetto chiuso

Data della firma CE 27 Luglio 2020

Data di avvio 1 Ottobre 2020

Data di completamento 30 Giugno 2023

Finanziato da

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Costo totale

€ 1 381 605,00

Contributo UE

€ 951 946,10

Coordinato da

ADVITOS GMBH
Germany

Periodic Reporting for period 2 - ADVOS-COVID-19 (Increasing Survival of Patients with Severe SARS-CoV-2 Infection and/or Multi Organ Failure by up to 30% with ADVOS - ADVanced Organ Support)

Periodo di rendicontazione: 2021-10-01 al 2023-06-30

Sintesi del contesto e degli obiettivi generali del progetto

ADVITOS` innovation – the ADVOS therapy system - has the potential to increase the survival of COVID-19 patients suffering from severe multi organ failure (MOF). First published clinical data show that ADVOS improves survival by up to 30% in critically ill patients on intensive care. The first COVID-19 patients with MOF have been treated with ADVOS in Germany with promising results. ADVITOS is a SME instrument Phase 2 beneficiary: ADVOS 880349 for device usability improvement, IoT integration, and market expansion. Following the urgent EU call for corona solutions, we applied for the blended finance option to speed up device production and installation in Germany and other EU countries. The applied funding and equity is necessary in therapy application, service and sales resources, as well as accelerated clinical evidence for medical indication guidance. Integrating fluid based blood oxygenation for comprehensive lung support and AI/digital capabilities will achieve additional therapy and outcome improvement. Each year, 60% of intensive care patients - 500,000 individuals in Western Europe and the US - die of MOF. The coronavirus outbreak will further increase this number dramatically as COVID-19 often leads to MOF. The innovative ADVOS therapy has the potential to revolutionize intensive care therapy of patients worldwide, as it is the first and only blood purification therapy combining liver, lung, kidney support and direct blood pH correction in 1 device (technology leader in removal of liver toxins and fast extracorporeal blood pH correction). It will help to save lives in the current epidemic. The ADVOS therapy is low-invasive as standard hemodialysis, so it can support by far more ICU patients than other devices (that have a higher risk profile).

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

The first reporting period for this project oversaw considerable progress in the clarification of the development and testing specifications deemed indispensable for a successful device development. The feasibility of the various methods being researched to integrate oxygenation into the ADVOS device is currently being evaluated, based on which a technical roadmap shall be put into place in the form of developmental activities.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

It is intended that following the completion of this project, it shall be technologically and fiscally viable to integrate oxygenation into the ADVOS device. this will help us realize the immense potential to revolutionize intensive care therapy for patients worldwide. This relates especially to the removal of CO2 (also carried out by the ADVOS device), which relieves the lungs and reduces the need/invasiveness of ventilation.

Company Logo